Category: Cardiovascular Systems Inc.
Medtech maker Cardiovascular Systems touts FDA clearance for a 60cm model of its Diamondback 360 peripheral orbital atherectomy system.
Minnesota-based Cardiovascular Systems (NSDQ:CSII) landed FDA clearance for a new size of its Diamondback 360 atherectomy system, used in treatment of peripheral artery disease.
Cardiovascular Systems unveils 1-year data from its ORBIT II study, reporting positive safety and efficacy outcomes as well as significant cost-savings for the Diamondback 360 atherectomy device.
Minnesota-based Cardiovascular Systems (NSDQ:CSII) this week unveiled 1-year outcomes of a pivotal study of its Diamondback 360 device in treating coronary artery disease.
Cardiovascular Systems shares surge nearly 20% after the medical device company's 2nd-quarter sales numbers and fiscal 3rd-quarter outlook beat expectations.
Cardiovascular Systems (NSDQ:CSII) shares surged nearly 20% today on better-than-expected fiscal 2nd-quarter numbers and a 3rd-quarter outlook that came out well ahead of Wall Street's forecast.
Cardiovascular Systems beats its estimates, raising more than $84 million through an underwritten public offering of its common stock.
Minnesota medical device maker Cardiovascular Systems (NSDQ:CSII) announced that it raised $84.5 million through sales of 3 million shares of its common stock.
Minnesota medical device maker Cardiovascular Systems plans to offer more than 2.1 million shares of its common stock, a potential take of $70 million based on the company's estimates.
Cardiovascular Systems (NSDQ:CSII) announced this week an upcoming stock offering worth up to $70 million in net proceeds, according to an early estimate.
Shares of Cardiovascular Systems hit a 52-week high after the medical device company beats expectations with its fiscal 1st-quarter results.
Cardiovascular Systems (NSDQ:CSII) shares posted a 52-week high just after noon today as investors reacted to strong fiscal 1st-quarter results.
Minnesota's Cardiovascular Systems gets a Wall Street boost after winning FDA approval for its Diamondback 360 Coronary Orbital Atherectomy System.